Source-grounded facts extracted from GLOBUS MEDICAL INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
GLOBUS MEDICAL INC shareholders approved Approval, on a non-binding, advisory basis, of the 2025 compensation of the Company’s named executive officers.
“The Company’s stockholders approved, on a non-binding, advisory basis the 2025 compensation of the Company’s named executive officers, as described in the Proxy Statement.”
GLOBUS MEDICAL INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-12-31 meeting.
“The Company’s stockholders approved the ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
GLOBUS MEDICAL INC shareholders approved Approval of 2021 Equity Incentive Plan Amendment.
“The Company’s stockholders approved the 2021 Equity Incentive Plan Amendment.”
GLOBUS MEDICAL INC shareholders approved Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders.
“Each of the director nominees listed below were elected by the Company’s stockholders at the Annual Meeting to serve a three-year term on the Board.”
GLOBUS MEDICAL INC reported full-year 2026 results: revenue $3.18 billion to $3.22 billion, EPS $4.70 to $4.80. Guidance raised.
“The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.70 to $4.80 from the previous range of $4.40 to $4.50.”
GLOBUS MEDICAL INC reported the first quarter ended March 31, 2026 results: revenue $759.9 million, net income $124.3 million, EPS $0.90.
“Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026: • Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis. • Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis. • GAAP net income for the quarter was $124.3 million. • GAAP diluted earnings per share (“EPS”) was $0.90, an increase of 66.6%.”
GLOBUS MEDICAL INC reported three-month period ended March 31, 2024 results: revenue $606.7 million, net income $7.1 million net loss, EPS ($0.05).
“Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 3 1 , 202 4 . · Worldwide net sales were $ 606.7 million , an increase of 119 . 3 % , or 119.8% on a constant currency basis · GAAP net loss for the quarter was $ 7. 1 million · GAAP d iluted e arnings p er share (“ EPS ”) was ( $0. 0”
GLOBUS MEDICAL INC reported the fiscal year ended December 31, 2023 results: revenue $ 1,568.5 million, net income $ 122.9 million, EPS $1.07. Guidance reaffirmed.
“EPS ”) was $0. 11 and non-GAAP diluted EPS was $0. 60 · Non-GAAP adjusted EBITDA was $ 1 70.0 million, or 27. 6 % of net sales Full Year 20 2 3 : · Worldwide net sales were $ 1,568.5 million , an increase of 53.3% on an actual and constant currency basis · GAAP n et income for the year was $ 122.9 million · GAAP d iluted EPS was $ 1.07 and n on-GAAP diluted EPS was $”
GLOBUS MEDICAL INC reported the fourth quarter ended December 31, 2023 results: revenue $ 616.5 million, net income $ 15.0 million, EPS $0.11.
“Worldwide net sales for the fourth quarter were $ 616.5 million”
Keith Pfeil changed role as Chief Operating Officer and Chief Financial Officer at GLOBUS MEDICAL INC.
“On February 5, 2024, Globus Medical, Inc. (the “Company”) issued a news release announcing the promotion of Keith Pfeil to Chief Operating Officer and Chief Financial Officer, effective as of February 1, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.